In Pharmacogenomics Reporter issue 1/6/2005, the article “FDA Clears Half of AmpliChip for Sale As an IVD; Rival Dx Shops Bear Down” characterized Paul Billings of LabCorp as saying “evidence, patient requests, quality, and liability concerns,” contributed to slow early P450 test demand. The text should have characterized these factors only as affecting demand.
Clarification
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.